Doojin Kim, MD
Neurology · Santa Monica, CANPI 1487679858
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by TG Therapeutics, Inc. at 48.2% of the total. 2025 is the largest year on record at $22,817, more than ten times the $668 reported in 2019. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 843 payments — averaging $47.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$19K
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$3K
- Novartis$2K
- Neurocrine Biosciences, Inc.$2K
- Argenx US, Inc.$2K
- plus $9K from 31 others
What the payments were for
- Consulting fees$1,7254%
- Speaking & faculty fees$16,53441%
- Travel & lodging$1,6984%
- Food & beverage$20,14650%
- Education$2661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 39 | $19,471 |
| AbbVie(2 entities) | 131 | $2,649 |
| Teva Pharmaceuticals USA, Inc. | 104 | $2,527 |
| Novartis | 150 | $2,412 |
| Neurocrine Biosciences, Inc. | 64 | $2,141 |
| Argenx US, Inc. | 1 | $1,725 |
| CSL Behring | 37 | $1,339 |
| UCB, Inc. | 52 | $1,326 |
| Biogen | 51 | $1,297 |
| EMD Serono, Inc. | 36 | $985 |
| AstraZeneca(2 entities) | 24 | $815 |
| Pfizer | 29 | $637 |
| Amgen | 21 | $529 |
| Biohaven Pharmaceuticals, Inc. | 19 | $372 |
| Lundbeck LLC | 13 | $342 |
| Lilly USA, LLC | 16 | $329 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $202 |
| Amneal Pharmaceuticals LLC | 3 | $164 |
| Boston Scientific | 2 | $123 |
| Mallinckrodt Hospital Products Inc. | 4 | $123 |
| Eisai Inc. | 1 | $122 |
| Greenwich Biosciences, Inc. | 4 | $106 |
| Genentech USA, Inc. | 3 | $88 |
| Impel Pharmaceuticals Inc. | 4 | $83 |
| Sunovion Pharmaceuticals Inc. | 4 | $82 |
| Acadia Pharmaceuticals Inc | 4 | $71 |
| SK Life Science, Inc. | 3 | $61 |
| Acorda Therapeutics, Inc | 2 | $49 |
| MDD US Operations, LLC | 3 | $48 |
| Bausch Health US, LLC | 1 | $25 |
| Sanofi | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Neurelis, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,369 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 46 | $52,529 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $22,015 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 17 | $17,560 |
| Nurtec OdtRimegepant Sulfate | 13 | $13,142 |
| EliquisApixaban | 12 | $11,625 |
| Emgality SyringeGalcanezumab-Gnlm | 15 | $10,660 |
| Emgality PenGalcanezumab-Gnlm | 12 | $10,329 |
| Levetiracetam | 113 | $5,902 |
| Rasagiline Mesylate | 26 | $4,056 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 131 | $2,895 |
| Carbamazepine ErCarbamazepine | 18 | $1,970 |
| Gabapentin | 90 | $1,871 |
| Primidone | 59 | $1,623 |
| Divalproex Sodium | 35 | $1,543 |
| Levetiracetam ErLevetiracetam | 21 | $1,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Eliquis | $637 | $24,76725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.
Other neurology in Santa Monica
- David KudrowSanta Monica$532K
- Santosh KesariSanta Monica$397K
- Andrew WooSanta Monica$273K
- Danny BenmosheSanta Monica$268K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.